Altium Capital Management LP Immunovant, Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $2.5 Million - $3.54 Million	80,000 New	80,000 $3.37 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $498,420 - $833,625	35,100 New	35,100 $665,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $2.35 Million - $3.81 Million	-335,041 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$9.4 - $16.85 $990,938 - $1.78 Million	105,419 Added 45.91%	335,041 $3.54 Million
Q1 2021 May 06, 2021	BUY	$13.08 - $49.6 $1.99 Million - $7.54 Million	152,000 Added 195.82%	229,622 $3.68 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $2.82 Million - $4.09 Million	77,622 New	77,622 $3.59 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.